Research and development of vaccines
Project disclaimer
Description
CEPI’s vision is a world in which epidemics and pandemics are no longer a threat to humanity. Going into the strategic period from 2022-2026, termed “CEPI 2.0”, CEPI aims to raise the bar to develop and scale vaccines and other promising biologic countermeasures even faster. The R&D community has moved with unprecedented speed in response to COVID-19, developing biological interventions like vaccines and monoclonal antibodies in less than 12 months. While these achievements are historic, what the world needs to avert the consequences of future epidemics and pandemics are countermeasures developed even faster. CEPI’s mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI believes safe and effective vaccine in 100 days from the moment that a pathogen is sequenced and/ or the need for a vaccine is recognised to initial availability for use should be the aspiration. Over the strategic period, CEPI aims to invest USD 3.5 billion across three overall strategic objectives:
Objectives
1)PREPARE for known epidemic and pandemic threats: End the acute phase of the COVID-19 pandemic by ensuring equitable access to a portfolio of COVID-19 vaccines favourable for LMICs and validate enabling science programmes to accelerate COVID-19 vaccine candidate development. Accelerate the development of vaccines and other biologic countermeasures against known high- risk pathogens, continuing vaccine development towards licensure for priority pathogens with a clear unmet need where vaccines could have an impact. Reduce the risk of further coronavirus pandemics, using the acceleration in vaccine technologies and methods due to COVID-19 response, with the ultimate objective to develop a broadly protective Betacoronavirus vaccine.2)TRANSFORM the response to the next novel threat: Using vaccine prototypes and platform innovations to give us a head-start on other novel threats. Investing and scaling critical enabling sciences to further accelerate rapid vaccine development. Investing in innovations to ensure vaccine manufacturing is cheaper, faster, and closer to an outbreak.3)CONNECT to enhance and expand global collaboration: Secure financing for epidemic preparedness and response, connecting countries, industry, public & private sectors from all over the world, and global health partners to develop vaccines and build commitment to preparedness and access. Improve coordination among key stakeholders to enable system readiness, driving for collaboration and solutions which will enable a faster system-wide response. Promote equitable access principles as the foundation of any effective global response.
Location
The country, countries or regions that benefit from this Programme.
Status Implementation
The current stage of the Programme, consistent with the International Aid Transparency Initiative's (IATI) classifications.
Programme Spend
Programme budget and spend to date, as per the amounts loaded in financial system(s), and for which procurement has been finalised.
Participating Organisation(s)
Help with participating organisations
- Commonwealth Scientific and Industrial Research Organisation
- INTACT Solutions Inc
- Serum Institute of India Private Limited
- Stevanato Group SpA
- 20Med Therapeutics B.V
- ACE Research Tokmeza
- ADVAC - Advanced Course of Vaccinology
- Abera Bioscience AB
- Aer Studios
- Affinivax, Inc.
- Africa Center for Disease Control (Africa CDC)
- African Medicines Agency
- Afrigen Biologics and Vaccines
- Aga Khan University
- Airfinity Limited
- Akagera Medicines, Inc.
- Algenex
- Altona Diagnostics Gmbh
- Amplitude Therapeutics, Inc
- Apriori Bio
- Aptar Stelmi SAS
- Aspen Pharma
- AstraZenica
- Auro Vaccines LLC
- Aurobindo
- Aurum Institute
- BERC Africa
- BNITM
- Barinthus Biotherapeutics Limited
- Batavia Biosciences B.V.
- Bavarian Nordic A/S
- Benin FORS
- Bharat Biotech
- BioNTech SE
- BioNet-Asia Co.,Ltd.
- Biofabri
- Biointelect
- Biologic Tech
- Biological E Limited
- Biomedical Primate Research Centre (BPRC)
- Boost Biopharma
- Bristows LLP
- BunyaVax B.V.
- CHUSJ
- CPI
- CR2O B.V.
- CSL Limited
- Celestial Therapeutics
- Centre for Vaccine Development Mali
- Chinese National Institutes for Food and Drug Control (NIFDC)
- Clarivate
- Clarivate Analytics (UK) Ltd
- Clover Biopharmaceuticals
- Codiak BioSciences, Inc.
- College of Medicine, Chungbuk National University
- Colorado State University
- Connected DMV
- CureVac
- DNA Script
- Dalhousie Univesity
- Defence Science and Technology Laboratory
- Diosynvax Ltd
- Duke University
- Dynavax
- EDUCATION AND TRAINING FOR HEALTH SCIENCES SRL A SOCIO UNICO
- Edes & Associates Consultant Limited
- Emergent BioSolutions
- Emervax Inc
- Epicentre
- European and Developing Countries Clinical Trials Partnership
- FIND
- Fiocruz
- Foundation for Innovative New Diagnostics
- GC Pharma
- GISAID
- Gennova Biopharmaceuticals Limited
- Ghana Food and Drug Authority
- Ginkgo Biosecurity
- Gorman Consulting
- Gritstone bio, Inc.
- HMRI
- Harvard Medical School
- ICON Government and Public Health Solutions, Inc.
- IDD Leipzig
- IDT biologica
- INTERNATIONAL ALLIANCE FOR BIOLOGICAL STANDARDIZATION
- IQVIA
- Imperial College
- Indian National Institute of Virology
- Inovio Pharmaceuticals
- Institut Nationale de Recherche Biomédicale
- Institut Paster
- Institut national de la santé et de la recherche médicale (INSERM)
- Institute of Epidemiology, Disease Control and Research (IEDCR)
- Institute of Tropical Medicine
- Integrum
- International AIDS Vaccine Initiative
- International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
- International Vaccine Access Center (IVAC) - JHSPH
- International Vaccine Institute
- International Vaccines Institute
- Intravacc
- Janssen
- Johns Hopkins University
- Jurata Thin Film
- KATHOLIEKE UNIVERSITEIT LEUVEN
- Kenema Government Hospital (KGH)
- Kenya AIDSVaccine Initiative (KAVI) – Institute of Clinical Research
- LSHTM
- Larissa
- Lemonex Inc
- LenioBio
- Linksbridge
- MERCK
- Margan Clinical Research Organization (MMARCRO)
- Massachusetts General Hospital
- Matalai Limited
- McManamey & McManamey
- Medicines and Healthcare products Regulatory Agency (MHRA)
- Medigen Vaccine Biologics Corp.
- MigVax Ltd
- Moderna
- Murdoch Children’s Research Institute (MCRI)
- Mutala Research
- Médecins Sans Frontières
- NEC OncoImmunity AS
- NIBSC
- National Autonomous University of Mexico
- National Emerging Infectious Diseases Laboratories
- National Research Council of Canada (NRC)
- Nexelis
- Nigeria NCDC
- Novavax
- Nuova Ompi S.r.l
- One Health Institute | UC Davis
- Oslo University Hospital
- P-95
- PATH
- PT Bio Farma
- Pan American Health Organization
- Panacea Biotec
- Pasteur Institute of Dakar
- Peter Doherty Institute NABs and gene sequencing
- Public Health Agency of Canada (PHAC)
- Public Health England
- Public Health Vaccines
- Pullman Grand Hotel de Kinshasa
- Q2 Solutions
- RVAC Medicines
- Regents of the University of Minnesota
- Rinda Ubuzima
- Robert Koch Institute
- SK bioscience
- Sabin Vaccine Institute
- SeromYx
- Shanghai Zerun Biotechnology Co., Ltd.
- Sichuan Clover Biopharmaceuticals
- Stevanato Group SpA
- Synexa Life Sciences
- THSTI
- TMC STRATEGIC CONSULTING LLC (THE MIND CO)
- TRIFT INNOVATION
- Taconic Biosciences, Inc.
- Taskforce for Global Health
- Technical University of Mombasa
- The Task Force for Global Health
- The University of Texas Medical Branch
- Themis Bioscience
- Tiba Biotec
- Transperfect
- Tulane University
- Turesol, LLC
- U.K. National Institute for Health Research (NIHR)
- UK - Department of Health and Social Care (DHSC)
- UK Health Security Agency
- UNITE Global Parliamentarians Network
- Uganda Virus Research Institute (UVRI)
- Universidad Nacional Autónoma de México (UNAM)
- Universiteit Gent
- Universiti Malaya
- University College London
- University of Aberta
- University of Alberta
- University of Antwerpen
- University of British Columbia
- University of California - UC Davies
- University of Cambridge
- University of Hong Kong
- University of North-Carolina
- University of Oxford, The
- University of Philippines
- University of Pittsburgh
- University of Queensland
- University of Saskatchewan’s (USask) Vaccine and Infectious Disease Organization (VIDO)
- University of Sheffield
- University of Tokyo
- University of Veterinary Medicine Hannover (TiHo)
- Université Gamal Abdel Nasser de Conakry
- VBI Vaccines Inc.
- Valneva
- Vaxxas
- Vaxxinity, Inc.
- Viroclinics Biosciences B.V
- Vismederi
- WHO
- WHO/EMRO
- Wageningen University & Research - Stichting Wageningen Research
- Wellcome LEAP
- Zalgen Labs
- Zoe Global Limited
- aVaxziPen
Sectors
Sector groups as a percentage of total Programme budget according to the OECD Development Assistance Committee (DAC) classifications.
Budget
A comparison across financial years of forecast budget and spend to date on the Programme.